Startups channel feed – Endpoints News

Startups channel feed

Torque takes tumor tech out of stealth with $25M backing, new CEO

8 years ago

Google backs I/O startup Arcus in $107M deal

8 years ago

Upstart Oyster Point has big plans for disrupting the ophthalmology space, but you'll have to wait for the details

8 years ago

Bill Gates and rich allies help fund an alt-biotech startup path for the gene expression experts at Exicure

8 years ago

Two years in, the team at NousCom bags $49M to fund first human studies of neoantigen drugs

8 years ago

California upstart Xyphos wants to tackle CAR-T's big problems

8 years ago

Atlas-incubated Kymera leaps out of stealth mode, joins the hunt for game-changing protein degradation drugs

8 years ago

Google’s GV and allies double down on Forty Seven with their second $75M round

8 years ago

With $500M-plus, a buyout and two new billion-dollar pacts, upstart Vir is ready to roll on infectious diseases

8 years ago

Pfizer, NEA back Cydan II's plans to launch a fresh slate of biotech startups focused on rare genetic diseases

8 years ago

Armed with $42.5M, Gemini embraces the Goldilocks strategy in bringing precision med to AMD

8 years ago

Four years after it imploded at Sanofi, John Hood is resurrecting the myelofibrosis drug fedratinib

8 years ago

Bain, RA back InflaRx’s $55M round after early study produces promising results

8 years ago

Medicxi kickstarts a new cancer drug developer with $19M launch round

8 years ago

Facebook billionaires Peter Thiel and Sean Parker backing a stealth immunotherapy biotech — report

8 years ago

Armed with a $47M round, Gates-backed Visterra aims at a PhIIb flu drug study

8 years ago

Backed by Big Pharma VCs, Palleon ramps up a new approach to immuno-oncology with a $48M startup round

8 years ago

Top scientists and BD execs craft Cullinan, a $150 million R&D portfolio shop focused on cancer

8 years ago

Genzyme vet David Meeker takes helm at stealthy KSQ with $76M and a new map for drug discovery

8 years ago

GSK spinout NeRRe splits the pipeline, creates its own spinout

8 years ago

Two young scientists bag $20M to perfect their CRISPR attack on disease-causing bacteria at upstart Eligo

8 years ago

Pfizer spins off drug orphans into a PhIII-ready startup backed by Bain to the tune of $103M

8 years ago

OrbiMed, RA Capital back a $26M raise for Realm’s two mid-stage drugs

8 years ago

With help from J&J, upstart Provention lands rights to two mid-stage IBD drugs and shoots for PhII

8 years ago

First page Previous page 67 68 697071 72 73 Next page Last page